Prime Medicine (PRME) Shares Outstanding (Weighted Average) (2021 - 2026)

Prime Medicine (PRME) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $177.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 35.31% year-over-year to $177.1 million; the trailing twelve-month figure through Mar 2026 stood at $177.1 million (up 35.31% YoY), and the FY2025 full-year result was $148.8 million, up 25.43% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $177.1 million, up from $148.8 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $177.1 million in Q1 2026 and bottomed at $19.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $104.5 million (2024), against an average of $97.4 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) soared 367.52%; it then climbed 15.52% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $33.9 million in 2022, then jumped by 168.42% to $91.0 million in 2023, then soared by 30.37% to $118.6 million in 2024, then increased by 25.43% to $148.8 million in 2025, then increased by 19.05% to $177.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $177.1 million (Q1 2026), $148.8 million (Q4 2025), and $160.5 million (Q3 2025), per Business Quant data.

Peer Comparison